Share

In This Section

Home / Resource Library Search

Resource Library Search Filter

Filter By Resource Library: Format Type
Filter By Resource Library: Topic

Resource Library Search

Based on available evidence correlating attainment of MRD negativity with outcomes, MRD assessment has been incorporated into ongoing clinical trials. Analyses will provide additional insight into the correlation between MRD and outcome. This monograph examines the available trial data and provides recommendations on how to incorporate MRD assessment into clinical management.
Clinical Advances in Hematology & Oncology
In adults with relapsed/refractory ALL receiving first salvage therapy, achievement of MRD negativity is an important therapeutic outcome. Patients who achieve MRD negativity with first salvage treatment and undergo SCT have the best long-term survival.
Cancer
This study prospectively evaluated the significance of MRD. Patients were treated with a uniform Polish Adult Leukemia Group 4?2002 protocol. MRD status was assessed after induction and consolidation by multiparametric flow cytometry.
British Journal of Hematology
Deeper methods of assessing for MRD in bone marrow in MM such as multiparameter flow cytometry (MFC) and NGS have been shown to be superior predictors of survival compared to traditional response assessment.1-4 However, MRD as a guide for clinical decision-making remains unproven, likely due to disparate patterns of MRD techniques and usage in clinical trials and clinical care. In light of the many uncertainties regarding MRD as a clinical decision-making tool and surrogate endpoint for clinical trials, we sought to understand contemporary clinician attitudes and practices toward the use and measurement of MRD in MM.
British Journal of Haematology
Here, we will address the currently utilized MRD assays, challenges in validation across labs and clinical trials, techniques in development, and future directions for successful clinical application of MRD in multiple myeloma.
Blood Reviews
Results reinforce the role of MRD detection by different strategies in patient prognosis and highlight the use of MRD as an endpoint for multiple myeloma treatment.
Blood Cancer Journal
We explore the important role of the clinical value of MRD use in the real-world practice in MM. We address new topics in the field of MRDs, including the importance of MRD dynamics and prediction of relapse.
Blood Advances
In patients with transplant-ineligible newly diagnosed multiple myeloma (NDMM), daratumumab reduced the risk of disease progression or death by 44% in MAIA (daratumumab/lenalidomide/dexamethasone [D-Rd]) and 58% in ALCYONE (daratumumab/bortezomib/melphalan/prednisone [D-VMP]). Minimal residual disease (MRD) is a sensitive measure of disease and response to therapy. MRD-negativity status and durability were assessed in MAIA and ALCYONE.
Blood
A fully-standardized EuroFlow 8�color antibody panel and laboratory procedure was stepwise designed to measure MRD in B-cell precursor ALL patients with a sensitivity of ?10?5, comparable to real-time quantitative polymerase chain reaction (RQ-PCR)�based MRD detection via antigen-receptor rearrangements.
Blood
This article shows that poor early MRD response, in contrast to conventional ALL risk factors, is an excellent tool to identify patients who may benefit from allogeneic SCT in the context of intensified adult ALL therapy.
Blood
Initial imatinib-based therapy of Ph+ adult ALL is associated with lower early mortality and higher CR rate. In adults with Ph+ ALL, allogeneic SCT in first CR prolongs relapse-free survival and OS.
Blood
Although levels of minimal residual disease (MRD) decrease below the detection limit in most adult patients with standard-risk ALL after consolidation treatment, about 30% of these patients will ultimately relapse. To evaluate the power of MRD monitoring as an indicator of impending relapse, we prospectively analyzed postconsolidation samples of 105 patients enrolled in the GMALL trial by real-time quantitative polymerase chain reaction (PCR) of clonal immune gene rearrangements.
Blood
Patients who were MRD negative had a higher probability of prolonged progression-free survival than patients with detectable residual disease, regardless of treatment group (RVD vs transplant), cytogenetic risk profile, or International Staging System disease stage at diagnosis. These results were similar after completion of maintenance therapy. Our findings confirm the value of MRD status, as determined by NGS, as a prognostic biomarker in multiple myeloma, and suggest that this approach could be used to adapt treatment strategies in future clinical trials.
Blood
Early response to therapy is one of the most important prognostic factors in acute leukemia, which prompted authors to investigate whether or not early immunophenotypic assessment of MRD could also be a valuable tool for predicting relapse in adult patients with ALL. For that purpose, this study analyzed the level of MRD during the initial phase of treatment (induction phase) by multiparameter flow cytometry in a series of 102 adolescent (older than 14 years) and adult patients with ALL.
Blood
MRD diagnostics has proven to be the strongest prognostic factor, allowing for risk group assignment into different treatment arms, ranging from significant treatment reduction to mild or strong intensification. Also in relapsed ALL patients and patients undergoing stem cell transplantation, MRD diagnostics is guiding treatment decisions.
Blood
Ten of 36 patients (28%) achieved an OS ?30 months in a blinatumomab study in relapsed/refractory acute lymphoblastic leukemia. Long-term survival may be associated with T-cell expansion, B-cell depletion, and a minimal residual disease response.
Blood
BCR-ABL1�positive cells outside the B-lineage compartment are found in 40% of adult patients with BCR-ABL1�positive BCP-ALL. Selection of preexisting CD19� subclones is a potential source of tumor escape after CD19-targeted therapies in adult Philadelphia chromosome�positive ALL.
Blood
The persistence of MRD during therapy is the strongest adverse prognostic factor in ALL. We developed a high-throughput sequencing method that universally amplifies antigen-receptor gene segments and identifies all clonal gene rearrangements (i.e., leukemia-specific sequences) at diagnosis, allowing monitoring of disease progression and clonal evolution during therapy.
Blood
Although advances in frontline therapy have yielded unprecedented improvement in long-term patient outcomes, surrogate markers of PFS and OS are needed. In this regard, achievement of stringent complete response (CR; sCR) after ASCT is associated with improvement in median PFS and OS.8,9 Similarly, minimal residual disease (MRD) testing has emerged as a sensitive measure of depth of response that strongly correlates with PFS and OS.
Blood
MRD is an established and sensitive prognostic tool to assess the depth of response during and after treatment of chronic lymphocytic leukemia CLL and to understand disease dynamics after treatment. Retracing these kinetics is paramount to understand which group of patients is at risk of relapsing despite initial MRD response. To this end, we here provide an analysis of clonal growth patterns in patients treated within the CLL14 trial.
Blood